plasmapheresis

Full title: The Effect on Quality of Life of Therapeutic Plasmapheresis and Intravenous Immunoglobulins on a Population of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients with Elevated β-Adrenergic and M3-Muscarinic Receptor Antibodies—A Pilot Study...

Effect on Quality of Life of Therapeutic Plasmapheresis in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients with Elevated β-Adrenergic and M3-Muscarinic Receptor Antibodies – a Pilot Study Boglárka Oesch-Régeni, Nicolas Germann, Georg Hafer, Dagmar Schmid, Norbert Arn [Line breaks...

Background Postural orthostatic tachycardia syndrome (POTS), one of the most common autonomic disorders, is associated with significant morbidity and functional impairment. Although several possible etiologies have been proposed, autoimmunity has emerged as one of the leading causes with...

Abstract A proportion of COVID-19 reconvalescent patients develop post-COVID-19 syndrome (PCS) including a subgroup fulfilling diagnostic criteria of Myalgic encephalomyelitis/Chronic Fatigue Syndrome (PCS/CFS). Recently, endothelial dysfunction (ED) has been demonstrated in these patients, but...

Highlights • Close to 20 distinct functionally active autoantibodies which target GPCR of the nervous system and renin-angiotensin system-related molecules were found significantly associated with the clinical severity of COVID-19 • Numerous clinical and laboratory similarities exist between...

Abstract Fibromyalgia syndrome (FMS) is characterized by widespread pain and tenderness, and patients typically experience fatigue and emotional distress. The etiology and pathophysiology of fibromyalgia are not fully explained and there are no effective drug treatments. Here we show that IgG...

Nature - molecular psychiatry Chronic post-COVID-19 syndrome and chronic fatigue syndrome: Is there a role for extracorporeal apheresis? - Bornstein et al Abstract As millions of patients have been infected by SARS-CoV-2 virus a vast number of individuals complain about continuing...

https://www.mdpi.com/2077-0383/9/8/2443

Heyho, short introduction from my side, im from germany ( english is not my native language so please overlook possible grammar mistakes :) I got CFS after an infection with the legionnaires disease in 2014. I tried a lot of different therapies by now (some examples: Rituximab, Rapamun) and im...

Dr. David M. Systrom of Brigham and Women’s Hospital (Boston) is confident that his team has objective evidence of small-fiber polyneuropathy (SFPN) in 40-50% of ME patients. Dr Systrom was interviewed by Llewelyn King in this video: . I put the timestamp at the part involved with SFPN but the...

Read more: https://www.hindawi.com/journals/mi/2008/792428/ This is an old-ish study, bit has some interesting ideas about neurological conditions. Though it doesn't mention ME directly, three of the references used to support the argument deal with 'CFS'. The theory goes that interrupted VNs...

https://doi.org/10.1371/journal.pone.0193672

1. What blood test can be given to determine whether an MECFS patient has the proliferative B cells in their bloodstream, that rituximab and other drugs would eliminate from the bloodstream? 2. Would it be helpful at all after receiving this kind of treatment to also have one or two sessions of...